Cargando…
History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic
To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705918/ https://www.ncbi.nlm.nih.gov/pubmed/34946093 http://dx.doi.org/10.3390/microorganisms9122491 |
_version_ | 1784622065171562496 |
---|---|
author | Meybeck, Agnès Huleux, Thomas Tétart, Macha Thill, Pauline Derdour, Vincent Bocket, Laurence Alidjinou, Enagnon Kazali Patoz, Pierre Robineau, Olivier Ajana, Faiza |
author_facet | Meybeck, Agnès Huleux, Thomas Tétart, Macha Thill, Pauline Derdour, Vincent Bocket, Laurence Alidjinou, Enagnon Kazali Patoz, Pierre Robineau, Olivier Ajana, Faiza |
author_sort | Meybeck, Agnès |
collection | PubMed |
description | To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed a SARS-CoV-2 serology. Among the 600 PLWHIV included, 16 have been infected with SARS-CoV-2. Symptoms consistent with COVID-19 were frequent both in SARS-CoV-2 positive and negative patients (67% vs. 32%, p = 0.02). Among SARS-CoV-2 infected patients, one (6%) has been hospitalized and five (31%) have been asymptomatic. Close contact with a confirmed COVID-19 case was the only factor associated with COVID-19 acquisition (40% vs. 13%, p = 0.01). The prevalence of COVID-19 in PLWHIV was 2.5%, half of the overall population estimate after the first wave of the pandemic in France. In conclusion, proportion of asymptomatic COVID-19 was high in PLWHIV. The prevalence of COVID-19 in PLWHIV was two times lower than in the general population. |
format | Online Article Text |
id | pubmed-8705918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87059182021-12-25 History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic Meybeck, Agnès Huleux, Thomas Tétart, Macha Thill, Pauline Derdour, Vincent Bocket, Laurence Alidjinou, Enagnon Kazali Patoz, Pierre Robineau, Olivier Ajana, Faiza Microorganisms Article To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV reference center in Northern France. PLWHIV completed a questionnaire about risk exposures and symptoms consistent with COVID-19 and performed a SARS-CoV-2 serology. Among the 600 PLWHIV included, 16 have been infected with SARS-CoV-2. Symptoms consistent with COVID-19 were frequent both in SARS-CoV-2 positive and negative patients (67% vs. 32%, p = 0.02). Among SARS-CoV-2 infected patients, one (6%) has been hospitalized and five (31%) have been asymptomatic. Close contact with a confirmed COVID-19 case was the only factor associated with COVID-19 acquisition (40% vs. 13%, p = 0.01). The prevalence of COVID-19 in PLWHIV was 2.5%, half of the overall population estimate after the first wave of the pandemic in France. In conclusion, proportion of asymptomatic COVID-19 was high in PLWHIV. The prevalence of COVID-19 in PLWHIV was two times lower than in the general population. MDPI 2021-12-01 /pmc/articles/PMC8705918/ /pubmed/34946093 http://dx.doi.org/10.3390/microorganisms9122491 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Meybeck, Agnès Huleux, Thomas Tétart, Macha Thill, Pauline Derdour, Vincent Bocket, Laurence Alidjinou, Enagnon Kazali Patoz, Pierre Robineau, Olivier Ajana, Faiza History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title | History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title_full | History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title_fullStr | History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title_full_unstemmed | History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title_short | History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic |
title_sort | history of covid-19 symptoms and seroprevalence of sars-cov-2 antibodies in hiv-infected patients in northern france after the first wave of the pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705918/ https://www.ncbi.nlm.nih.gov/pubmed/34946093 http://dx.doi.org/10.3390/microorganisms9122491 |
work_keys_str_mv | AT meybeckagnes historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT huleuxthomas historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT tetartmacha historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT thillpauline historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT derdourvincent historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT bocketlaurence historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT alidjinouenagnonkazali historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT patozpierre historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT robineauolivier historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic AT ajanafaiza historyofcovid19symptomsandseroprevalenceofsarscov2antibodiesinhivinfectedpatientsinnorthernfranceafterthefirstwaveofthepandemic |